| Literature DB >> 28123752 |
Maryse C J Osté1, Eva Corpeleijn2, Gerjan J Navis1, Charlotte A Keyzer1, Sabita S Soedamah-Muthu3, Else van den Berg1, Douwe Postmus2, Martin H de Borst1, Daan Kromhout4, Stephan J L Bakker1.
Abstract
OBJECTIVE: The incidence of new-onset diabetes after transplantation (NODAT) and premature mortality is high in renal transplant recipients (RTR). We hypothesized that a Mediterranean Style diet protects against NODAT and premature mortality in RTR. RESEARCH DESIGN AND METHODS: A prospective cohort study of adult RTR with a functioning graft for >1 year. Dietary intake was assessed with a 177-item validated food frequency questionnaire. Patients were divided based on a 9-point Mediterranean Style Diet Score (MDS): low MDS (0-4 points) versus high MDS (5-9 points). A total of 468 RTR were eligible for analyses. Logistic multivariable regression analyses were used to study the association of MDS with NODAT and Cox multivariable regression models for the association with all-cause mortality.Entities:
Keywords: Dietary Patterns; Mortality; Post-Transplant Diabetes; Renal Transplantation
Year: 2017 PMID: 28123752 PMCID: PMC5253439 DOI: 10.1136/bmjdrc-2016-000283
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Frequency distribution of the Mediterranean Diet Score (MDS) in the overall RTR population (468 participants). RTR, renal transplant recipients.
Baseline characteristics of the overall RTR population and according to groups based on the MDS
| Overall RTR | Group 1 MDS 0–4 | Group 2 MDS 5–9 | p Value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 51.3±13.2 | 49.9±13.9 | 52.5±12.4 | 0.03 |
| Male gender, n (%) | 265 (56.6) | 124 (57.1) | 141 (56.2) | 0.83 |
| Smoking behavior (current smoker), n (%) | 60 (12.8) | 29 (13.4) | 31 (12.4) | 0.64 |
| Total energy intake, kcal/day | 2199±656 | 2168±696 | 2225±619 | 0.35 |
| Physical activity score (time×intensity) | 5605 (2885–8647) | 5060 (2070–8385) | 6000 (3480–8700) | 0.03 |
| Weight, kg | 78.9±15.8 | 78.1±16.2 | 79.6±15.5 | 0.31 |
| Body composition | ||||
| Height, cm | 173.9±9.7 | 173.4±10.6 | 174.3±9.0 | 0.30 |
| BMI, kg/m2 | 26.0±4.5 | 25.9±4.6 | 26.1±4.5 | 0.60 |
| Waist circumference, cm | ||||
| Men | 99.1±12.1 | 98.7±12.2 | 99.5±12.1 | 0.98 |
| Women | 93.0±15.8 | 92.6±15.3 | 93.4±16.3 | 0.68 |
| Circulation | ||||
| Heart rate, bpm | 67.6±12.0 | 67.8±12.3 | 67.4±11.8 | 0.72 |
| SBP, mm Hg | 135.3±17.0 | 135.7±16.3 | 135.0±17.7 | 0.68 |
| DBP, mm Hg | 83.0±11.0 | 83.3±11.1 | 82.8±11.0 | 0.61 |
| Renal function | ||||
| eGFR, mL/min per 1.73 m2 | 53.1±20.2 | 52.3±21.6 | 53.7±18.8 | 0.45 |
| Laboratory parameters | ||||
| Triglycerides, mmol/L | 1.6 (1.2–2.1) | 1.7 (1.2–2.3) | 1.5 (1.1–2.0) | 0.04 |
| HDL cholesterol, mmol/L | 1.4±0.5 | 1.4±0.4 | 1.5±0.5 | 0.001 |
| Fasting glucose, mmol/L | 5.1 (4.7–5.5) | 5.1 (4.7–5.5) | 5.0 (4.7–5.5) | 0.51 |
| Hepatitis C virus, n (%) | 6 (1.3) | 3 (1.4) | 3 (1.2) | 0.86 |
| Cytomegalovirus, n (%) | ||||
| Primary infection | 99 (21.2) | 48 (22.1) | 51 (20.3) | 0.63 |
| Reactivation | 80 (17.1) | 38 (17.5) | 42 (16.7) | 0.69 |
| Primary renal disease | ||||
| Polycystic kidney disease, n (%) | 103 (22.0) | 47 (21.7) | 56 (22.3) | 0.87 |
| Nephrosclerosis, n (%) | 139 (29.7) | 67 (30.9) | 72 (28.7) | 0.61 |
| Transplant characteristics | ||||
| Transplant vintage, years | 5.6 (2.1–12.3) | 5.2 (2.2–12.3) | 5.8 (1.8–12.3) | 0.80 |
| Living donor, n (%) | 168 (35.9) | 70 (32.3) | 98 (39.0) | 0.20 |
| Pre-emptive transplant, n (%) | 84 (17.9) | 32 (14.7) | 52 (20.7) | 0.09 |
| Dialysis duration, months | 37.0 (16.0–60.0) | 46.0 (15.0–63.0) | 32.0 (17.0–56.0) | 0.30 |
| Age donor, years | 43.0±15.5 | 42.6±15.0 | 43.4±15.9 | 0.61 |
| Cold ischemia time, hours | 14.0 (3.0–21.0) | 16.0 (3.0–21.0) | 12.0 (3.0–21.0) | 0.06 |
| Warm ischemia time, minutes | 40 (33–50) | 42 (33–51) | 39 (34–48) | 0.25 |
| Acute rejection, n (%) | 114 (24.4) | 49 (22.6) | 65 (25.9) | 0.41 |
| Medication | ||||
| Cyclosporine, n (%) | 178 (38.0) | 82 (37.8) | 96 (38.2) | 0.92 |
| Tacrolimus, n (%) | 79 (16.9) | 44 (20.3) | 35 (13.9) | 0.07 |
| mTOR inhibitor, n (%) | 5 (1.1) | 2 (0.9) | 3 (1.2) | 0.76 |
| Prednisolone dose, mg | 10.0 (7.5–10.0) | 10.0 (7.5–10.0) | 10.0 (7.5–10.0) | 0.70 |
| Cumulative prednisolone dose, g | 18.3 (7.4–38.1) | 18.3 (7.8–36.6) | 18.2 (7.4–40.4) | 0.86 |
| Diuretics, n (%) | 158 (33.8) | 76 (35.0) | 82 (32.7) | 0.59 |
| β blocker, n (%) | 284 (60.7) | 126 (58.1) | 158 (62.9) | 0.28 |
| ACE inhibitor, n (%) | 158 (33.8) | 73 (33.6) | 85 (33.9) | 0.96 |
| Angiotensin II receptor blocker, n (%) | 71 (15.2) | 39 (18.0) | 32 (12.7) | 0.12 |
| Statins, n (%) | 232 (49.6) | 100 (46.1) | 132 (52.6) | 0.15 |
Data are represented as mean±SD, median (IQR) or n (%). Differences were tested by t-test or Mann-Whitney U test for continuous variables and with χ2 test for categorical variables.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; MDS, Mediterranean Diet Score; RTR, renal transplant recipients; SBP, systolic blood pressure.
Median intake of the components of the Mediterranean Diet Score
| Group 1 (0–4) | Group 2 (5–9) | |||
|---|---|---|---|---|
| Men | Women | Men | Women | |
| Ratio monounsaturated: saturated fatty acids | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 1.0 (0.9–1.1) | 1.0 (0.9–1.1) |
| Legumes, nuts and soy products (g/day) | 29 (16–39) | 28 (18–40) | 52 (38–72) | 44 (32–71) |
| Cereals (g/day) | 176 (128–240) | 134 (107–178) | 210 (170–257) | 175 (141–206) |
| Fruit (g/day) | 77 (34–137) | 105 (57–211) | 135 (81–234) | 211 (97–249) |
| Vegetables (g/day) | 57 (32–77) | 64 (48–87) | 100 (74–140) | 124 (92–153) |
| Meat products (g/day) | 109 (82–128) | 94 (77–116) | 90 (70–115) | 79 (58–99) |
| Dairy products (g/day) | 357 (234–511) | 399 (253–492) | 330 (211–481) | 369 (217–507) |
| Fish (%) | 34 | 34 | 57 | 67 |
| Alcohol (%) | 67 | 84 | 48 | 80 |
Figure 2Kaplan-Meier survival curves. Probability of survival for NODAT (A) and all-cause mortality (B) for both group 1 and group 2. NODAT, new-onset diabetes after transplantation.
Multiple logistic regression analysis
| Group 1 (0–4) | Group 2 (5–9) | ||
|---|---|---|---|
| 17 (7.8%) | 5 (2.0%) | ||
| Number of events | OR (95% CI) | p Value | |
| Model 1 | 1.00 (ref) | 0.24 (0.09 to 0.66) | 0.006 |
| Model 2 | 1.00 (ref) | 0.23 (0.08 to 0.63) | 0.004 |
| Model 3 | 1.00 (ref) | 0.22 (0.08 to 0.62) | 0.004 |
| Model 4 | 1.00 (ref) | 0.24 (0.08 to 0.69) | 0.008 |
| Model 5 | 1.00 (ref) | 0.23 (0.08 to 0.63) | 0.004 |
| Model 6 | 1.00 (ref) | 0.23 (0.08 to 0.65) | 0.005 |
| Model 7 | 1.00 (ref) | 0.18 (0.06 to 0.54) | 0.002 |
| Model 8 | 1.00 (ref) | 0.23 (0.08 to 0.63) | 0.004 |
The Mediterranean diet is associated with a lower risk to develop NODAT.
Model 1, crude.
Model 2, adjustment for age and sex.
Model 3, model 2+adjustment for cyclosporine, tacrolimus and prednisolone dose.
Model 4, model 2+adjustment for pre-emptive transplantation and cold ischemia time.
Model 5, model 2+adjustment for total energy intake.
Model 6, model 2+adjustment for smoking and physical activity.
Model 7, model 2+adjustment for triglycerides and HDL-cholesterol concentrations.
Model 8, model 2+adjustment for time between transplantation and baseline.
HDL, high-density lipoprotein; NODAT, new-onset diabetes after transplantation.
Cox Regression analysis
| Group 1 (0–4) | Group 2 (5–9) | ||
|---|---|---|---|
| 29 (13.4%) | 21 (8.4%) | ||
| Number of events | HR (95% CI) | p Value | |
| Model 1 | 1.00 (ref) | 0.62 (0.35 to 1.09) | 0.09 |
| Model 2 | 1.00 (ref) | 0.51 (0.29 to 0.89) | 0.02 |
| Model 3 | 1.00 (ref) | 0.52 (0.29 to 0.92) | 0.03 |
| Model 4 | 1.00 (ref) | 0.52 (0.27 to 0.99) | 0.05 |
| Model 5 | 1.00 (ref) | 0.51 (0.29 to 0.89) | 0.02 |
| Model 6 | 1.00 (ref) | 0.57 (0.22 to 1.03) | 0.06 |
| Model 7 | 1.00 (ref) | 0.57 (0.32 to 1.02) | 0.06 |
| Model 8 | 1.00 (ref) | 0.50 (0.29 to 0.89) | 0.02 |
The Mediterranean diet is associated with a lower risk of mortality during follow-up.
Model 1, crude.
Model 2, adjustment for age and sex.
Model 3, model 2+adjustment for cyclosporine, tacrolimus and prednisolone dose.
Model 4, model 2+adjustment for pre-emptive transplantation and cold ischemia time.
Model 5, model 2+adjustment for total energy intake.
Model 6, model 2+adjustment for smoking and physical activity.
Model 7, model 2+adjustment for triglycerides and HDL-cholesterol concentrations.
Model 8, model 2+adjustment for time between transplantation and baseline.
HDL, high-density lipoprotein.